Role of CYP2C19 alleles in the management of recurrent ischemic stroke
- 1 April 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 9 (2) , 140-144
Abstract
Purpose of review CYP2C19 is the primary enzyme involved in the activation of clopidogrel, an antiplatelet agent used for secondary stroke prevention. An individual9s CYP2C19 alleles are used to understand their CYP2C19-clopidogrel metabolizer phenotype. Single nucleotide polymorphisms of the CYP2C19 gene result in altered metabolism of this prodrug. Recent findings Three ischemic stroke cases were treated with clopidogrel. Despite confirming adequate drug exposure, medication adherence, and ruling out drug-drug interactions, all had recurrent ischemic stroke. Each case had a CYP2C19 *2/*17 genotype, categorizing them as intermediate clopidogrel metabolizers. Even with the gain-of-function allele, the loss-of-function allele resulted in lack of prodrug activation, leading to decreased efficacy in platelet inhibition. Summary These cases illustrate the importance of a thoughtful approach to secondary stroke prevention and demonstrate the utility of pharmacogenomic testing in clopidogrel hyporesponders. Recognition of the importance of CYP2C19 genotyping has the potential to enable better selection of appropriate secondary prevention strategies.Keywords
This publication has 19 references indexed in Scilit:
- Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic AttackCirculation, 2017
- Association BetweenCYP2C19Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic AttackJAMA, 2016
- CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) StudyJournal of the American Heart Association, 2015
- Cardiovascular Disease Pharmacogenomics2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular ProceduresAmerican Journal of Neuroradiology, 2012
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine DiphosphateJACC, 2010
- Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapyJournal of Thrombosis and Haemostasis, 2010
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986